Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus secukinumab in adults with moderate to severe plaque psoriasis
NL-OMON46698Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in plaque psoriasis comparing Risankizumab with Secukinumab (2 arms). Primary endpoints: PASI 90 at Week 52 and PASI 90 at Week 16. Started Nov 2018; status: completed.
02
Drugs
risankizumabsecukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON46698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46698.